Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remternetug in Healthy Chinese Participants
NCT07346495Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2026
- Primary completion
- Aug 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1 trial of remternetug in Alzheimer's disease (AD) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration. Started Jan 2026; status: completed.
02
Drugs
remternetug
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07346495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07346495.